(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of -1.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Enanta Pharmaceuticals's revenue in 2025 is $64,463,000.On average, 2 Wall Street analysts forecast ENTA's revenue for 2025 to be $1,319,041,931, with the lowest ENTA revenue forecast at $1,318,935,048, and the highest ENTA revenue forecast at $1,319,148,814. On average, 2 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,328,554,509, with the lowest ENTA revenue forecast at $1,248,392,330, and the highest ENTA revenue forecast at $1,408,716,688.
In 2027, ENTA is forecast to generate $1,306,002,216 in revenue, with the lowest revenue forecast at $1,192,599,454 and the highest revenue forecast at $1,419,404,978.